Special Issue: Resistance to Targeted Therapies in Human Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Special Issue: Resistance to Targeted Therapies in Human Cancer

Published:2023-01-31 Issue:2 Volume:11 Page:414
ISSN:2227-9059
Container-title:Biomedicines
language:en
Short-container-title:Biomedicines

Author:

Lee Tae-Won¹,Choi Hee-Joo²³⁴,Lee Kyung-Min¹⁴⁵⁶^ORCID,Lee Jeong-Yeon²⁴

Affiliation:

1. Department of Life Science, College of Natural Sciences, Hanyang University, Seoul 04763, Republic of Korea

2. Department of Pathology, College of Medicine, Hanyang University, Seoul 04763, Republic of Korea

3. Hanyang Biomedical Research Institute, Hanyang University, Seoul 04763, Republic of Korea

4. Hanyang Institute of Bioscience and Biotechnology, Hanyang University, Seoul 04763, Republic of Korea

5. Research Institute for Natural Sciences, Hanyang University, Seoul 04763, Republic of Korea

6. Research Institute for Convergence of Basic Sciences, Hanyang University, Seoul 04763, Republic of Korea

Abstract

Cancer is the second leading cause of death worldwide, accounting for approximately 10 million deaths in 2020 [...]

Funder

National Research Foundation of Korea

Publisher

MDPI AG

Subject

General Biochemistry, Genetics and Molecular Biology,Medicine (miscellaneous)

Link

https://www.mdpi.com/2227-9059/11/2/414/pdf

Reference13 articles.

1. Montoya, S., Soong, D., Nguyen, N., Affer, M., Munamarty, S.P., and Taylor, J. (2021). Targeted Therapies in Cancer: To Be or Not to Be, Selective. Biomedicines, 9.

2. Juengel, E., Schnalke, P., Rutz, J., Maxeiner, S., Chun, F.K., and Blaheta, R.A. (2021). Antiangiogenic Properties of Axitinib versus Sorafenib Following Sunitinib Resistance in Human Endothelial Cells-A View towards Second Line Renal Cell Carcinoma Treatment. Biomedicines, 9.

3. The tumor microenvironment at a glance;Balkwill;J. Cell Sci.,2012

4. Mollah, F., and Varamini, P. (2021). Overcoming Therapy Resistance and Relapse in TNBC: Emerging Technologies to Target Breast Cancer-Associated Fibroblasts. Biomedicines, 9.

5. Understanding the tumor immune microenvironment (TIME) for effective therapy;Binnewies;Nat. Med.,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3